Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial (vol 22, pg 494, 2023)

被引：0
|
作者：
Granit, V
Benatar, M.
Kurtoglu, M.
机构：
来源：
LANCET NEUROLOGY | 2023年 / 22卷 / 09期
关键词：
D O I：
10.1016/S1474-4422(23)00282-X
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E10 / E10
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial
    Stimming, Erin Furr
    Claassen, Daniel
    Kayson, Elise
    Goldstein, Jody
    Mehanna, Raja
    Zhang, Hui
    Liang, Grace S.
    Haubenberger, Dietrich
    LANCET NEUROLOGY, 2023, 22 (06): : 494 - 504
  • [2] KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia
    Hauser, Robert A.
    Factor, Stewart A.
    Marder, Stephen R.
    Knesevich, Mary Ann
    Ramirez, Paul M.
    Jimenez, Roland
    Burke, Joshua
    Liang, Grace S.
    O'Brien, Christopher F.
    AMERICAN JOURNAL OF PSYCHIATRY, 2017, 174 (05): : 476 - 484
  • [3] ACTION-HD: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PROSPECTIVE CROSSOVER TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF BUPROPION IN HUNTINGTON'S DISEASE
    Gelderblom, H.
    Fischer, W.
    Landwehrmeyer, B.
    McLean, T.
    Reilmann, R.
    Saft, C.
    Suessmuth, S.
    Priller, J.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2012, 83 : A57 - A58
  • [4] Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study
    Reilmann, Ralf
    Anderson, Karen E.
    Feigin, Andrew
    Tabrizi, Sarah J.
    Leavitt, Blair R.
    Stout, Julie C.
    Piccini, Paola
    Schubert, Robin
    Loupe, Pippa
    Wickenberg, Anna
    Borowsky, Beth
    Rynkowski, Gail
    Volkinshtein, Rita
    Li, Thomas
    Savola, Juha-Matti
    Hayden, Michael
    Gordon, Mark Forrest
    LANCET NEUROLOGY, 2024, 23 (03): : 243 - 255
  • [5] Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial
    Angus, D.
    Herd, C.
    Stone, C.
    Stout, J.
    Wieler, M.
    Reilmann, R.
    Ritchie, C. W.
    Dorsey, E. R.
    Helles, K.
    Kayson, E.
    Oakes, D.
    Rosas, H. D.
    Vaughan, C.
    Panegyres, P. K.
    Ames, D.
    Goh, A.
    Agarwal, P.
    Churchyard, A.
    Murathodizic, M.
    Chua, P.
    Germaine, D.
    Lim, L.
    Mack, H.
    Loy, C.
    Griffith, J.
    Mitchell, P.
    Corey-Bloom, J.
    Gluhm, S.
    Goldstein, J.
    Levi, L.
    Margolis, R.
    Yoritomo, N.
    Janicki, S.
    Marder, K.
    Clouse, R.
    Singer, C.
    Moore, H.
    Padron, N.
    Kostyk, S.
    Daley, A.
    Segro, V.
    Kumar, R.
    Anderson, K.
    Drazinic, C.
    Hennig, B.
    Nance, M.
    Molho, E.
    Criswell, S.
    LeDoux, M. S.
    Guyot, S.
    LANCET NEUROLOGY, 2015, 14 (01): : 39 - 47
  • [6] SAFETY AND TOLERABILITY OF SELISISTAT FOR THE TREATMENT OF HUNTINGTON'S DISEASE: RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TRIAL
    Reilmann, R.
    Squitieri, F.
    Priller, J.
    Saft, C.
    Mariotti, C.
    Suessmuth, S. D.
    Nemeth, A. H.
    Tabrizi, S. J.
    Quarrell, O.
    Craufurd, D.
    Rickards, H.
    Rosser, A.
    Darpo, B.
    Tessari, M.
    Szynol, A.
    Fischer, D. F.
    Frost, C.
    Farmer, R. E.
    Landwehrmeyer, G. B.
    Westerberg, G.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 : A102 - A102
  • [7] A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL EVALUATING CYSTEAMINE IN HUNTINGTON'S DISEASE
    Bonneau, Dominique
    Bachoud-Levi, Anne-Catherine
    Durr, Alexandra
    Goizet, Cyril
    Azulay, Jean-Philippe
    Simonin, Clemence
    Tranchant, Christine
    Calvas, Fabienne
    Krystkowiak, Pierre
    Olivier, Audrey
    Saudou, Frederic
    Maison, Patrick
    Allain, Philippe
    Verny, Christophe
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 : A101 - A102
  • [8] Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
    Garcia de Yebenes, Justo
    Landwehrmeyer, Bernhard
    Squitieri, Ferdinando
    Reilmann, Ralf
    Rosser, Anne
    Barker, Roger A.
    Saft, Carsten
    Magnet, Markus K.
    Sword, Alastair
    Rembratt, Asa
    Tedroff, Joakim
    LANCET NEUROLOGY, 2011, 10 (12): : 1049 - 1057
  • [9] KINECT 3: A randomized, double-blind, placebo-controlled phase 3 trial of valbenazine (NBI-98854) for tardive dyskinesia
    Factor, S. A.
    Hauser, R. A.
    Siegert, S.
    Liang, G. S.
    O'Brien, C. F.
    MOVEMENT DISORDERS, 2016, 31 : S692 - S692
  • [10] KINECT 3: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine (NBI-98854) for Tardive Dyskinesia
    Hauser, Robert
    Factor, Stewart
    Marder, Stephen
    Knesevich, Mary Ann
    Ramirez, Paul Michael
    Jimenez, Roland
    Burke, Joshua
    Liang, Grace
    O'Brien, Christopher
    NEUROLOGY, 2016, 86
12345